Amgen Inc. (AMGN) Shares Bought by PGGM Investments
PGGM Investments increased its stake in Amgen Inc. (NASDAQ:AMGN) by 9.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 725,684 shares of the medical research company’s stock after buying an additional 64,011 shares during the period. PGGM Investments owned about 0.10% of Amgen worth $110,413,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in AMGN. Oak Associates Ltd. OH boosted its stake in shares of Amgen by 0.3% in the first quarter. Oak Associates Ltd. OH now owns 210,710 shares of the medical research company’s stock valued at $31,592,000 after buying an additional 581 shares in the last quarter. National Pension Service boosted its stake in shares of Amgen by 4.2% in the first quarter. National Pension Service now owns 378,322 shares of the medical research company’s stock valued at $56,722,000 after buying an additional 15,376 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock valued at $964,334,000 after buying an additional 132,632 shares in the last quarter. Prudential PLC boosted its stake in shares of Amgen by 41.4% in the first quarter. Prudential PLC now owns 1,062,893 shares of the medical research company’s stock valued at $159,359,000 after buying an additional 311,157 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Amgen by 1.0% in the first quarter. Legal & General Group Plc now owns 3,263,086 shares of the medical research company’s stock valued at $489,239,000 after buying an additional 32,086 shares in the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded up 0.32% during mid-day trading on Monday, hitting $167.34. 2,514,609 shares of the company’s stock traded hands. Amgen Inc. has a one year low of $138.06 and a one year high of $176.85. The firm’s 50-day moving average price is $171.51 and its 200-day moving average price is $161.44. The stock has a market cap of $125.23 billion, a PE ratio of 17.12 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.57 EPS. On average, analysts forecast that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.39%. The ex-dividend date was Monday, August 15th. Amgen’s payout ratio is presently 40.90%.
Several equities research analysts recently weighed in on AMGN shares. Goldman Sachs Group Inc. restated a “buy” rating and issued a $202.00 price target on shares of Amgen in a research report on Wednesday, June 15th. Vetr upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 price objective on the stock in a research report on Monday, June 13th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 price objective on the stock in a research report on Wednesday, June 29th. BMO Capital Markets reiterated a “buy” rating and set a $186.00 price objective on shares of Amgen in a research report on Tuesday, July 12th. Finally, Jefferies Group reiterated a “buy” rating and set a $187.00 price objective on shares of Amgen in a research report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Amgen currently has a consensus rating of “Buy” and a consensus target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.